This article examines the impact of cardiovascular diseases on the course of HIV and mortality. The risk of developing cardiovascular diseases (CVD) is associated with gender and virological and immunological status. Modifiable and non-modifiable risk factors are an integral part of the development of cardiovascular diseases, and in the context of existing HIV disease, new risk factors associated with the processes occurring in the immune system are added. Antiretroviral therapy drugs have side effects that affect the cardiovascular system. Existing methods of preventing and prognosticating CVD do not take into account new risk factors associated with HIV infection, which complicates the process of risk reduction.
Kaliberdenko et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: